Elaina Vayntrub, MD
Internal Medicine · Ypsilanti, MINPI 1770573958
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,650 of the $22,233 with a category attached, or 61.4%. Lilly USA, LLC accounts for 91.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $20,402, more than ten times the $497 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $130.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$20K
- Novo Nordisk$1K
- Amgen$263
- Ascendis Pharma Endocrinology Inc$121
- Acelrx Pharmaceuticals, Inc.$110
- Endo Pharmaceuticals Inc.$70
- plus $281 from 9 others
What the payments were for
- Consulting fees$4,02518%
- Speaking & faculty fees$13,65061%
- Travel & lodging$2,17410%
- Food & beverage$2,34011%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $20,295 |
| Novo Nordisk | 85 | $1,093 |
| Amgen | 17 | $263 |
| Ascendis Pharma Endocrinology Inc | 1 | $121 |
| Acelrx Pharmaceuticals, Inc. | 1 | $110 |
| Endo Pharmaceuticals Inc. | 4 | $70 |
| Vivus LLC | 1 | $65 |
| Currax Pharmaceuticals LLC | 4 | $57 |
| Alvogen Inc | 2 | $35 |
| Heron Therapeutics, Inc. | 1 | $28 |
| Nalpropion Pharmaceuticals LLC | 2 | $28 |
| Pfizer | 1 | $21 |
| Rhythm Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,233 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 394 | $433,030 |
| OzempicSemaglutide | 100 | $123,503 |
| Teriparatide | 36 | $87,237 |
| WegovySemaglutide | 58 | $84,934 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 52 | $15,584 |
| LinzessLinaclotide | 22 | $12,316 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 55 | $11,724 |
| TrulicityDulaglutide | 12 | $11,285 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,352 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 15 | $1,040 |
| Topiramate | 82 | $684 |
| Bupropion Hcl SrBupropion Hcl | 16 | $456 |
| Nystatin | 23 | $312 |
| Simvastatin | 44 | $305 |
| Ondansetron Hcl | 50 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $20,295 | $444,315406 claims |
| Novo NordiskOzempic, Wegovy | $1,093 | $208,437158 claims |
| Alvogen IncTeriparatide | $35 | $87,23736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Ypsilanti
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.